THROMBOELASTOGRAPHY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Thromboelastography Market is estimated to be valued at USD 796.2 Mn in 2026 and is expected to reach USD 1,303.8 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 7.3% from 2026 to 2033.

Thromboelastography is a technique for evaluating the effectiveness of blood coagulation. Although, it is increasingly being utilized in resuscitations in emergency rooms, critical care units, and labor and delivery rooms. The test is mostly used in anesthesia and surgery. Thromboelastography (TEG) is a non-invasive test that analyses whole blood's ability to clot quantitatively. The goal of this in vitro test is to identify and measure dynamic alterations in a blood sample's viscoelastic characteristics that occur during clotting under low shear stress. A Thromboelastography is a specially created system, which is used to conduct the test. The device uses two chambers to examine a blood sample in parallel while reducing the possibility of measurement and sampling errors. The body's defence against potentially fatal exsanguination is based on the blood's capacity to coagulate, or change from a liquid to a solid form. The thrombosis process typically only occurs locally at the site of arterial damage, leaving the remaining blood in circulation in a liquid state.

Figure 1: Global Thromboelastography Market Share (%) Analysis, by Type,2026

Global Thromboelastography Market– Drivers

Increasing number of product launches by market players is expected to drive the global thromboelastography market growth over the forecast period. For instance, on April 28, 2022, Nordic Biomarker is a Sweden based manufacturer of advance reagent, calibrators and controls for coagulation and clinical chemistry analyzers launched vWF Antigen. “Von Willebrand factor”, which is a large protein that plays an important part in the coagulation process. Up to 1% of people have von Willebrand Disease (vWD), the most prevalent inherited bleeding illness. The diagnosis denotes either a lack of sufficient quantity or quality of vWF, which causes abnormal bleeding in the patient. A vWF Antigen assay is one of the several processes that make up the difficult diagnosing procedure.

The increase in number of research and development activities is expected to boost the growth of global thromboelastography market over the forecast period. For instance, on January 10, 2020, an article published in Multidisciplinary Digital Publishing Institute (MDPI), Viscoelastic tests results does not clearly split platelet count from function. Moreover, extensive thrombin generation from standard activated viscoelasticity assays activates platelets through protease-activated receptors, bypassing other pathways. For this reason, standard viscoelastic tests cannot be used to assess platelet reactivity under the action of aspirin or P2Y12 inhibitors. To overcome this problem a new technique was developed called as thromboelastography platelet mapping, it is a modification of the standard TEG and it evaluates platelet function through direct activation of arachidonic acid (AA) and adenosine diphosphate (ADP) receptors.

As noted, these patients’ blood clots do not appear to have resolved.

Global Thromboelastography Market– Restraints

Standard platelet concentrates (PCs) are to be stored at 22 °C and it has shelf life of 5 days. Due to storage temperatures, bacterial contamination of PCs can lead to life-threatening infections in transfusion patients. For instance, on December 06, 2021, a recent article published in Association for the Advancement of Blood & Biotherapies (AABB), stated that, Thromboelastometry assays have been applied to assess standard platelet concentrates quality globally. A study using thromboelastography on buffy coat standard platelet concentrates revealed that this method may not be sensitive enough to detect quality changes associated with normal storage.

Global Thromboelastography Market– Regional Analysis

On the basis of region, the global thromboelastography market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position in the market during the forecast period, owing to the increasing number of approvals by regulatory authorities is expected to drive the market growth over the forecast period. For instance, Idarucizumab, a monoclonal antibody specific for the dabigatran molecule, has now received the U.S. FDA approval for use as an antidote. Similar antibodies are being developed to ask the FDA for permission to reverse xabans (Xa) inhibitors like Andexanet Alpha. Since the thrombin time and the ecarin clotting time, which can quantify coagulation with the Non-Vitamin K antagonist oral anticoagulants (NOACs), are not widely available, it is likely that the Thromboelastography (TEG)/ Thromboelastometry (ROTEM) will be used to determine the efficacy of these antidotes.

Figure 2: Global Thromboelastography Market Value (US$ Mn), by Region, 2026

Global Thromboelastography Market – Competitive Landscape

Major players operating in the global thromboelastography market include Lepu Medical Technology (Beijing) Co.,Ltd., Render Biotech Co., Haemonetics Corporation, TA Instruments, HemaCore LLC, 5-Diagnostics, Xenometrix AG, Framar Hemologix srl, Instrumentation Laboratory, Medirox AB, Diagnostica Stago, Life Diagnostica, SYCOmed e.K., Nordic Biomarker, and Shenzhen Ultra-Diagnostics Biotec. Co., Ltd